Vaccines with an LTB adjuvant
US6793928B1 · kind B1 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 13, 2000 |
| Grant date | Sep 21, 2004 |
| Priority date | — |
| Expiry date | Dec 13, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/16234
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a vaccine containing at least one particulate immunogen and an adjuvanting amount of B subunits of heat-labile enterotoxin characteristic of E. Coli. More in particular, this invention relates to vaccines wherein the adjuvanting LTB is free from contaminating A subunits or holotoxin. To this end, preferably, use is made of LTB prepared by recombinant DNA techniques. The particulate immunogens can relate to or can be derived from e.g. viruses, bacteria or fungi. This vaccine is particularly suitable for the induction of a protective response against said particulate immunogen upon mucosal (e.g. intra-nasal) administration. It was found that such administration results in both systemic and mucosal protection against the pathogen to which the particulate immunogen relates.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.